Heart failure and anemia: Mechanisms and pathophysiology

Heart Failure Reviews

Volumn 13, Issue 4, 2008, Pages 379-386

  Anand, Inder S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Heart failure; High output heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; TRANSCRIPTION FACTOR GATA 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANEMIA; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; ERYTHROPOIESIS; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODILUTION; HEMODYNAMICS; HEMOGLOBIN DETERMINATION; HIGH OUTPUT HEART FAILURE; HUMAN; HYPOXIA; IRON DEFICIENCY ANEMIA; IRON METABOLISM; KIDNEY DYSFUNCTION; MICROCYTIC ANEMIA; NEUROENDOCRINE SYSTEM; NONHUMAN; OXYGEN DISSOCIATION CURVE; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE OXYGENATION; VASODILATATION;

ANEMIA; HEART FAILURE; HUMANS;

EID: 43749123844     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9088-8     Document Type: Article

References (84)

1. Disease Statistics (2005) NHLBI FY 2005 Fact Book: 37-56
2. Rosamond W, Flegal K, Friday G et al (2007) Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5):e69-e171
3. Komajda M (2004) Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 10(1 Suppl):S1-S4
4. Kosiborod M, Smith GL, Radford MJ et al (2003) The prognostic importance of anemia in patients with heart failure. Am J Med 114(2):112-119
5. Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE) J Am Coll Cardiol 41(11):1933-1939
6. Tang YD, Katz SD (2006) Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 113(20):2454-2461
7. O'Meara E, Clayton T, McEntegart MB et al (2006) Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the candesartan in Aeart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 113(7):986-994
8. Horwich TB, Fonarow GC, Hamilton MA et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780-1786
9. Al-Ahmad A, Rand WM, Manjunath G et al (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38(4):955-962
10. Anand I, McMurray JJ, Whitmore J et al (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2):149-154
11. Anand IS, Kuskowski MA, Rector TS et al (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 112(8):1121-1127
12. Mancini DM, Katz SD, Lang CC et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2):294-299
13. Silverberg DS, Wexler D, Blum M et al (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35(7):1737-1744
14. Silverberg DS, Wexler D, Sheps D et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 37(7):1775-1780
15. Opasich C, Cazzola M, Scelsi L et al (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232-2237
16. Anand IS, Rector T, Deswal A et al (2006) Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 27(Suppl 1):485
17. Maggioni AP, Opasich C, Anand I et al (2005) Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11(2):91-98
18. Philipp S, Ollmann H, Schink T et al (2005) The impact of anaemia and kidney function in congestive heart failure and preserved systolic function. Nephrol Dial Transplant 20(5):915-919
19. Witte KK, Desilva R, Chattopadhyay S et al (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147(5):924-930
20. Cromie N, Lee C, Struthers AD (2002) Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 87(4):377-378
21. Westenbrink BD, Visser FW, Voors AA et al (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well Eur Heart J 28(2):166-171
22. Sandek A, Bauditz J, Swidsinski A et al (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50(16):1561-1569
23. Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96(2):526-534
24. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107(2):223-225
25. de Silva R, Rigby AS, Witte KK, et al (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98(3):391-398
26. Nanas JN, Matsouka C, Karageorgopoulos D et al (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485-2489
27. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352(10):1011-1023
28. Eckardt KU, Koury ST, Tan CC et al (1993) Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia. Kidney Int 43(4):815-823
29. Bauer C, Kurtz A (1989) Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol 51:845-856
30. Bachmann S, Le Hir M, Eckardt KU (1993) Co-localization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41(3):335-341
31. Mole DR, Ratcliffe PJ (2007) Cellular oxygen sensing in health and disease. Pediatr Nephrol, published online, October 23.
32. Nangaku M (2006) Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 17(1):17-25
33. Anand IS, Ferrari R, Kalra GS et al (1989) Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80(2):299-305
34. McCullough PA, Lepor NE (2005) Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 6(Suppl 3):S4-S12
35. Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6(Suppl 3):S13-S21
36. McClellan WM, Flanders WD, Langston RD et al (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 13(7):1928-1936
37. Volpe M, Tritto C, Testa U et al (1994) Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74(5):468-473
38. George J, Patal S, Wexler D et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165(11):1304-1309
39. van der Meer P, Voors AA, Lipsic E et al (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44(1):63-67
40. Jensen JD, Eiskjaer H, Bagger JP et al (1993) Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin. J Intern Med 233(2):125-130
41. Pham I, Andrivet P, Sediame S et al (2001) Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 31(2):103-109
42. Deswal A, Petersen NJ, Feldman AM et al (2001) Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055-2059
43. Anand IS, Latini R, Florea VG et al (2005) C-reactive protein in heart failure: Prognostic value and the effect of valsartan. Circulation 112(10):1428-1434
44. Rauchhaus M, Koloczek V, Volk H et al (2000) Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 76(2-3):125-133
45. Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18(8):555-559
46. Means RT Jr (2003) Recent developments in the anemia of chronic disease. Curr Hematol Rep 2(2):116-121
47. Macdougall IC, Cooper AC (2002) Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17(Suppl 11):39-43
48. Nemeth E, Rivera S, Gabayan V et al (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271-1276
49. Mrug M, Stopka T, Julian BA et al (1997) Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100(9):2310-2314
50. Fyhrquist F, Karppinen K, Honkanen T et al (1989) High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 226(4):257-260
51. Albitar S, Genin R, Fen-Chong M et al (1998) High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13(5):1206-1210
52. van der Meer P, Lipsic E, Westenbrink BD et al (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112(12):1743-1747
53. Androne AS, Katz SD, Lund L et al (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107(2):226-229
54. Anand IS, Veall N, Kalra GS et al (1989) Treatment of heart failure with diuretics: Body compartments, renal function and plasma hormones. Eur Heart J 10(5):445-450
55. Kalra PR, Anagnostopoulos C, Bolger AP et al (2002) The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 39(12):1901-1908
56. Anand IS, Chandrashekhar Y, Ferrari R et al (1993) Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70(4):357-362
57. Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83(3):415-426
58. Oski FA, Marshall BE, Cohen PJ et al (1971) The role of the left-shifted or right-shifted oxygen-hemoglobin equilibrium curve Ann Intern Med 74(1):44-46
59. Metivier F, Marchais SJ, Guerin AP et al (2000) Pathophysiology of anaemia: Focus on the heart and blood vessels. Nephrol Dial Transplant 15(Suppl 3):14-18
60. Brewer GJ (1974) 2,3-DPG and erythrocyte oxygen affinity. Annu Rev Med 25:29-38
61. Schmidt W, Boning D, Braumann KM (1987) Red cell age effects on metabolism and oxygen affinity in humans. Respir Physiol 68(2):215-225
62. Anand IS, Chandrashekhar Y, Wander GS et al (1995) Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 25(6):1402-1407
63. Ni Z, Morcos S, Vaziri ND (1997) Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 52(1):195-201
64. Anand IS, Ferrari R, Kalra GS et al (1991) Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy. Circulation 83(6):1880-1887
65. Datta BN, Silver MD (1975) Cardiomegaly in chronic anemia in rats and man experimental study including ultrastructural, histometric, and stereologic observations. Lab Invest 32(4):503-514
66. Olivetti G, Quaini F, Lagrasta C et al (1992) Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 141(1):227-239
67. Rakusan K, Cicutti N, Kolar F (2001) Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am J Physiol Heart Circ Physiol 280(3):H1407-H1414
68. Ishani A, Weinhandl E, Zhao Z et al (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45(3):391-399
69. Go AS, Yang J, Ackerson LM et al (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation 113(23):2713-2723
70. Berry C, Norrie J, Hogg K et al (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151(6):1313-1321
71. Felker GM, Shaw LK, Stough WG et al (2006) Anemia in patients with heart failure and preserved systolic function. Am Heart J 151(2):457-462
72. Brucks S, Little WC, Chao T et al (2004) Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 93(8):1055-1057
73. Lauer MS, Evans JC, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70(13):1180-1184
74. Levin A (2001) Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant 16(Suppl 2):7-11
75. Levin A (2002) Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge Kidney Int Suppl 80:35-38
76. Parfrey PS, Foley RN, Wittreich BH et al (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16(7):2180-2189
77. Roger SD, McMahon LP, Clarkson A et al (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15(1):148-156
78. Levin A (2007) The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 16(3):267-271
79. Mall G, Huther W, Schneider J et al (1990) Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5(1):39-44
80. McCullough PA, Lepor NE (2005) The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: Implications for prognosis and treatment. Rev Cardiovasc Med 6(1):1-10
81. Collins AJ (2003) The hemoglobin link to adverse outcomes. Adv Stud Med 3(3C):S194-S197
82. Anker SD, Coats AJ (1999) Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest 115(3):836-847
83. Silverberg DS, Wexler D, Blum M et al (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18(1):141-146
84. van Veldhuisen DJ, McMurray JJ (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9(2):110-112